Lumatix Biotech

Lumatix Biotech is an innovative tools and platform company developing the Solaris® System, the world's first light-controlled affinity chromatography platform. This technology replaces traditional, harsh pH-based elution methods with gentle, digitally controlled light switching, offering significant potential improvements in purification yield, product quality, and process efficiency for antibody-based therapeutics. As a pre-revenue, private company, Lumatix is positioned to disrupt the established chromatography market by addressing critical bottlenecks in the manufacturing of sensitive biologics, including cell and gene therapies. Its success hinges on commercial adoption, platform validation at scale, and competition against entrenched industry incumbents.

Light-controlled affinity chromatography using photo-switchable ligands (Protein A/G/L) for gentle, pH-neutral antibody and biomolecule purification. Commercialized as the Solaris® System, comprising a capsule with monolithic matrix, a light engine, and a control unit.

Competes directly with established chromatography resin and system providers like Cytiva, Thermo Fisher Scientific, and Merck KGaA, whose Protein A products dominate the market. Also competes with alternative gentle elution technologies (e.g., salt gradients, competitive elution) and novel chromatography approaches. Differentiation is based on the unique light-switching mechanism enabling precise, pH-neutral control.